Known targets — ChEMBL curated mechanism
ACHECHRM1CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNG
The experimentally established mechanism targets of Iodide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 4/20 | 0.49 |
| ▸ | RAB9A | P51151 | 2/20 | 0.49 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.45 |
| ▸ | DNMT3L | Q9UJW3 | 1/20 | 0.45 |
| ▸ | DNMT3A | Q9Y6K1 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 4/20 | 0.41 |
| ▸ | GUSB | P08236 | 1/20 | 0.41 |
| ▸ | AGPAT2 | O15120 | 1/20 | 0.41 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 2/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Iodide SCHEMBL3498356 | 0.88 | DNMT1 (0.35) | NPC1RAB9ADNMT1DNMT3LDNMT3A | |
| SCHEMBL3499609 | 0.86 | DNMT1 (0.36) | NPC1RAB9ADNMT1DNMT3LDNMT3A | |
| Iodide SCHEMBL3501443 | 0.86 | ROCK1 (0.46) | NPC1RAB9AMAPTALDH1A1SMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL3497424 | 0.85 | DNMT1 (0.35) | NPC1RAB9ADNMT1DNMT3LDNMT3A | |
| SCHEMBL13312577 | 0.85 | MEN1 (0.46) | NPC1RAB9AMAPTALDH1A1SMN1; SMN2 | |
| Iodide SCHEMBL9380644 | 0.78 | ROCK1 (0.52) | NPC1RAB9ADNMT1DNMT3LDNMT3A | |
| SCHEMBL3501270 | 0.75 | DNMT1 (0.75) | NPC1RAB9ADNMT1DNMT3LDNMT3A | |
| SCHEMBL3239682 | 0.75 | DNMT1 (0.53) | DNMT1DNMT3LDNMT3AMEN1KMT2A | |
| SCHEMBL3500285 | 0.74 | CYP1A2 (0.47) | RAB9ALMNAMAPTHTTNPSR1 | |
| SCHEMBL291198 | 0.71 | TERT (0.67) | NPC1RAB9AMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100137566-A1 | Compounds and Methods Used to Treat Infectious Diseases | CYTOKINE PHARMASCIENCES, INC (US) | 2010-06-03 | — | — | US | disclosed |
| US-20060014760-A1 | Compounds and methods of use to treat infectious diseases | BUKRINSKY MICHAEL I | 2006-01-19 | — | — | US | disclosed |
| US-6906076-B2 | Compounds and methods of use to treat infectious diseases | CYTOKINE PHARMASCIENCES, INC. (US) | 2005-06-14 | — | — | US | disclosed |
| US-20040053815-A1 | Compounds and methods of use to treat infectious diseases | FERRING BV (NL) | 2004-03-18 | — | — | US | disclosed |
| EP-0865434-B1 | COMPOUNDS AND THEIR USE TO TREAT INFECTIOUS DISEASES | PICOWER INST MED RES (US) | 2003-12-17 | — | — | EP | disclosed |
| US-6649797-B2 | Contacting protein with a compound that is capable of stable reversible binding with basic amino acid residues of nuclear localization signal of protein for inactivating a nuclear localization signal of a protein | THE PICOWER INSTITUTE FOR MEDICAL RESEARCH | 2003-11-18 | — | — | US | disclosed |
| US-20020077271-A1 | Compounds and methods of use to treat infectious diseases | FERRING BV (NL) | 2002-06-20 | — | — | US | disclosed |
| US-6297253-B1 | INACTIVATING A NUCLEAR LOCALIZATION SIGNAL OF A PROTEIN COMPRISING CONTACTING THE PROTEIN WITH AN ARYL CARBONYL COMPOUND THAT FORMS STABLE REVERSIBLE COVALENT INTERACTIONS WITH NEIGHBORING BASIC AMINO ACID RESIDUES | THE PICOWER INSTITUTE FOR MEDICAL RESEARCH | 2001-10-02 | — | — | US | disclosed |
| US-5840893-A | TREATING MALARIA, HUMAN IMMUNODEFICIENCY VIRUS INFECTIONS | THE PICOWER INSTITUTE FOR MEDICAL RESEARCH (US) | 1998-11-24 | — | — | US | disclosed |
| WO-1998016515-A1 | COMPOUNDS AND METHODS TO TREAT INFECTIOUS DISEASES | THE PICOWER INSTITUTE FOR MEDICAL RESEARCH (US) | 1998-04-23 | — | — | WO | disclosed |
| US-5733932-A | VIRICIDES MARKING AND BLOCKING SPECIFIC VIRAL PROTEINS | THE PICOWER INSTITUTE FOR MEDICAL RESEARCH (US) | 1998-03-31 | — | — | US | disclosed |
| US-5703086-A | TREATMENT OF HIV INFECTIONS | THE PICOWER INSTITUTE FOR MEDICAL RESEARCH (US) | 1997-12-30 | — | — | US | disclosed |
| US-5620983-A | BLOCKING MOVEMENT OF VIRAL GENOME PARTICLES THROUGH NUCLEAR MEMBRANE IN TERMINALLY DIFFERENTIATED CELLS TO PREVENT VIRAL INFECTIONS | THE PICOWER INSTITUTE FOR MEDICAL RESEARCH (US) | 1997-04-15 | — | — | US | disclosed |
| US-5574040-A | DIALKANOYLPHENYLPYRIMIDINE DERIVATIVES | PICOWER INSTITUTE FOR MEDICAL RESEARCH (US) | 1996-11-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060014760-A1 | Compounds and methods of use to treat infectious diseases | KPNA1, PHAX, NFATC1 | NPC1 31/4885RAB9A 3554/4885DNMT1 2539/4885 |
| US-20100137566-A1 | Compounds and Methods Used to Treat Infectious Diseases | KPNA1, NFATC1, MAVS | NPC1 25/4885RAB9A 3324/4885DNMT1 2519/4885 |
| US-20020077271-A1 | Compounds and methods of use to treat infectious diseases | KPNA1, PHAX, NFATC1 | NPC1 31/4885RAB9A 3554/4885DNMT1 2539/4885 |
| US-20040053815-A1 | Compounds and methods of use to treat infectious diseases | KPNA1, PHAX, NFATC1 | NPC1 31/4885RAB9A 3554/4885DNMT1 2539/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.